Michael Gunyoung Lee

Array ( [id] => 16991809 [patent_doc_number] => 20210230229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => VIRAL VECTORS EXHIBITING IMPROVED GENE DELIVERY PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/055318 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990297 [patent_doc_number] => 20210228717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => MULTIANALYTE IMMUNOASSAY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/051019 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761052 [patent_doc_number] => 20210106633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => NEOADJUVANT CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/044645 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17044645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720437 [patent_doc_number] => 20210087584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => INCREASING TISSUE SPECIFIC GENE DELIVERY BY CAPSID MODIFICATION [patent_app_type] => utility [patent_app_number] => 16/980821 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16620044 [patent_doc_number] => 20210038697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => VIRUS-LIKE NANOCAPSID FOR ORAL DELIVERY OF INSULIN [patent_app_type] => utility [patent_app_number] => 16/969143 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596620 [patent_doc_number] => 20210023151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => ONCOLYTIC VACCINIA VIRUS EXPRESSING IMMUNE CHECKPOINT BLOCKADE FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/980282 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16571022 [patent_doc_number] => 20210010028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => INSECT CELL MANUFACTURED PARTIAL SELF-COMPLEMENTARY AAV GENOMES [patent_app_type] => utility [patent_app_number] => 16/978288 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555747 [patent_doc_number] => 20210000895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => EXOSOME TARGETING OF CD4+ EXPRESSING CELLS [patent_app_type] => utility [patent_app_number] => 16/976277 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16976277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511622 [patent_doc_number] => 20200390879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => HUMAN JAPANESE ENCEPHALITIS VIRUS ANTIBODIES AND METHODS OF USE THEREFOR [patent_app_type] => utility [patent_app_number] => 16/971761 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22514 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16750937 [patent_doc_number] => 20210102946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => PROBE FOR UNIVERSAL DETECTION OF CIRCULATING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 16/970163 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552393 [patent_doc_number] => 20230250402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 6A [patent_app_type] => utility [patent_app_number] => 16/961609 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532379 [patent_doc_number] => 20220110988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => PSEUDORABIES VIRUS FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 16/966345 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19209545 [patent_doc_number] => 11998580 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Group B adenovirus-containing formulation [patent_app_type] => utility [patent_app_number] => 16/965549 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 13 [patent_no_of_words] => 15420 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657087 [patent_doc_number] => 20220177552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Binding Molecule Having Neutralizing Activity Against Middle East Respiratory Syndrome-Coronavirus [patent_app_type] => utility [patent_app_number] => 16/966248 [patent_app_country] => US [patent_app_date] => 2018-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688663 [patent_doc_number] => 20210071139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Identifying Epigenetic And Transcriptional Targets To Prevent And Reverse T Cell Exhaustion [patent_app_type] => utility [patent_app_number] => 16/759665 [patent_app_country] => US [patent_app_date] => 2018-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282733 [patent_doc_number] => 20200276335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/753322 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452879 [patent_doc_number] => 20200362305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => EFFICIENT INFECTION OF PRIMARY KERATINOCYTES BY HPV16 [patent_app_type] => utility [patent_app_number] => 16/966588 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681789 [patent_doc_number] => 20200095558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => REBOOTING OF SYNTHETIC BACTERIOPHAGE GENOME IN L-FORM BACTERIA [patent_app_type] => utility [patent_app_number] => 16/484487 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484487 [rel_patent_id] =>[rel_patent_doc_number] =>)